When and where will Oryzon Genomics, S.A. present the iadademstat data?

Oryzon Genomics, S.A. will present the data at the EHA Annual Congress taking place June 11-14, 2026 in Stockholm, Sweden. The company said the data will be presented in two poster sessions.

What is Oryzon Genomics, S.A. and what does it do?

Oryzon Genomics, S.A. is a clinical-stage biopharmaceutical company focused on epigenetics. The company is evaluating its selective LSD1 inhibitor iadademstat in clinical trials for AML.

What are Oryzon Genomics, S.A.’s identifying codes?

Oryzon Genomics, S.A. is identified in the announcement by ISIN Code ES0167733015 and the symbol ORY.

What results did Oryzon Genomics, S.A. report from the ALICE-2 trial?

Oryzon Genomics, S.A. reported that, as of the February 2026 data cutoff, the triplet combination of iadademstat, azacitidine and venetoclax in the ALICE-2 trial had an overall response rate of 100% among evaluable patients (n=14/15). The complete response rate was 79% (n=11/14), while the composite complete remission rate was 93% (n=13/14).

What overall survival result did Oryzon Genomics, S.A. report for ALICE-2?

Oryzon Genomics, S.A. reported that, after a median follow-up of 6 months, the estimated 12-month OS rate in ALICE-2 was 74%. The company said updated data with additional patients and more mature responses will be presented at the EHA meeting.

Which treatments are being evaluated in Oryzon Genomics, S.A.’s ALICE-2 trial?

The ALICE-2 trial is evaluating a triplet combination of iadademstat, azacitidine and venetoclax in newly diagnosed AML. The trial is identified as NCT06357182.

What results did Oryzon Genomics, S.A. report from the FRIDA trial?

Oryzon Genomics, S.A. reported a composite complete remission rate of 67% (n=12/18) in updated data from a heavily pre-treated relapsed or refractory FLT3mut AML population in the FRIDA trial. The company said the data evaluated iadademstat plus the standard-of-care treatment gilteritinib.

Which patients and treatment does Oryzon Genomics, S.A.’s FRIDA trial cover?

The FRIDA expansion cohort covers patients with FLT3-mutated relapsed or refractory AML. It evaluates iadademstat plus gilteritinib, and the trial is identified as NCT05546580.

What did Oryzon Genomics, S.A. say about the safety of iadademstat-based combinations?

Oryzon Genomics, S.A. said the ALICE-2 and FRIDA findings continue to support the clinical activity and favourable safety profile of iadademstat-based combinations in AML. The company described the ALICE-2 triplet combination and the FRIDA combination as having favourable safety findings in the announced data.

What does Oryzon Genomics, S.A. say about its plans for iadademstat?

Chief Executive Officer Carlos Buesa said Oryzon Genomics, S.A. is envisaging an accelerated clinical development plan for iadademstat in the first-line AML setting. He linked this statement to the strength of the emerging data and did not provide further details of the plan in the announcement.

How many ALICE-2 patients does Oryzon Genomics, S.A. expect the updated data to cover?

Carlos Buesa said the updated ALICE-2 results will come from a larger patient cohort, likely representing approximately 75–80% of the planned enrollment. He said the company believes this will provide a more mature assessment of the safety and efficacy of the triplet combination.

When will Oryzon Genomics, S.A. present the ALICE-2 poster at EHA 2026?

Oryzon Genomics, S.A.’s ALICE-2 poster is scheduled for Saturday, June 13, 2026, from 6:45-7:45 pm CEST. The title is “Updated Safety and Efficacy Results of a Phase Ib Investigation of the LSD1 Inhibitor Iadademstat (ORY-1001) in Combination with Azacitidine and Venetoclax in Newly Diagnosed AML”, with Abstract ID EHA-4924.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon to Present Updated Iadademstat Data in Two AML Trials at EHA 2026

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon to Present Updated Iadademstat Data in Two AML Trials at EHA 2026

Published Wednesday, 13 May 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Operational update
Published: Wednesday, 13 May 2026
Source announcement: oryzon.com

Key figures
Measure	Figure	Period
Overall response rate (ORR)	100%	As of the February 2026 data cutoff
Complete response (CR) rate	79% (n=11/14)	As of the February 2026 data cutoff
Composite complete remission (CRc: CR+CRh+CRi) rate	93% (n=13/14)	As of the February 2026 data cutoff
Estimated 12-month OS rate	74%	After a median follow-up of 6 months
CRc rate	67% (n=12/18)	Not stated

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced presentations of updated data from two Phase Ib trials.

The trials evaluate iadademstat, a selective LSD1 inhibitor, in AML; ALICE-2 combines it with azacitidine and venetoclax.
EHA Annual Congress will take place June 11-14, 2026, in Stockholm, Sweden.
At the February 2026 cutoff, ALICE-2 reported ORR 100%, CR 79% (n=11/14), and CRc 93% (n=13/14) among evaluable patients (n=14/15).
FRIDA data showed a CRc rate of 67% (n=12/18) for iadademstat plus gilteritinib in heavily pre-treated relapsed/refractory FLT3mut AML.
The ALICE-2 and FRIDA posters are scheduled for June 13 and June 12, 2026, respectively, both from 6:45-7:45 pm CEST.

The company said the larger ALICE-2 cohort is likely to represent approximately 75–80% of planned enrollment and that it is envisaging an accelerated clinical development plan in first-line AML.

Investor FAQs

Oryzon Genomics, S.A. announced that updated clinical data from two Phase Ib trials of its selective LSD1 inhibitor iadademstat in acute myeloid leukemia (AML) will be presented at the European Hematology Association (EHA) Annual Congress. The presentations will cover the ALICE-2 and FRIDA trials.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
Published: Wednesday, 13 May 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…